Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Prostate Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

  • Details

ClinicalTrials.gov ID: NCT02817633
Diagnosis Type: NSCLC
USOR Number: 17063

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Melanoma

Clinical Trial at: Texas Oncology - Paris

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

  • Details

ClinicalTrials.gov ID: NCT02817633
Diagnosis Type: NA
USOR Number: 17063

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Paris

POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

  • Details

ClinicalTrials.gov ID: NCT03280303
Diagnosis Type: NA
USOR Number: 16128

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Rectal Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy

  • Details

ClinicalTrials.gov ID: NCT03597295
Diagnosis Type: NA
USOR Number: 18134

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

  • Details

ClinicalTrials.gov ID: NCT03318939
Diagnosis Type: NSCLC
USOR Number: 17143

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Texas Oncology - Paris

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

GI Stromal Tumor (GIST)

Clinical Trial at: Texas Oncology - Paris

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

  • Details

ClinicalTrials.gov ID: NCT03465722
Diagnosis Type: NA
USOR Number: 18016

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Paris

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Paris

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

  • Details

ClinicalTrials.gov ID: NCT03535740
Diagnosis Type: NSCLC
USOR Number: 18076

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Colon Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

  • Details

ClinicalTrials.gov ID: NCT02817633
Diagnosis Type: NA
USOR Number: 17063

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Texas Oncology - Paris

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Paris

(I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

  • Details

ClinicalTrials.gov ID: NCT03155997
Diagnosis Type: NA
USOR Number: 17082

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Paris

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Paris

An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

  • Details

ClinicalTrials.gov ID: NCT01897571
Diagnosis Type: Non-Hodgkins
USOR Number: 16248

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Paris

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

  • Details

ClinicalTrials.gov ID: NCT02952534
Diagnosis Type: NA
USOR Number: 16237

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Texas Oncology - Paris

A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

  • Details

ClinicalTrials.gov ID: NCT02872714
Diagnosis Type: NA
USOR Number: 15228

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Renal Cancer

Clinical Trial at: Texas Oncology - Paris

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

  • Details

ClinicalTrials.gov ID: NCT02811861
Diagnosis Type: NA
USOR Number: 16145

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Paris

ONT-380-206 - Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206)

  • Details

ClinicalTrials.gov ID: NCT02614794
Diagnosis Type: NA
USOR Number: 16195

  • Practice Details

3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031

More Details View Practice Page

Pages